KOSPI Market, Korea Exchange · 207940
SAMSUNG BIOLOGICS Co., Ltd. price
Price history, key statistics, and comparable assets for SAMSUNG BIOLOGICS Co., Ltd..
₩1,556,000.00
+2.77% (₩42,000.00)
Historical prices
Price history
Intraday through long-term closing prices. Choose 1 day, 1 week, 1 month, 6 months, year to date, 1 year, 5 years, or all available history.
Point-in-time fields
Key statistics
- Previous close
- ₩1,514,000.00
- Open
- ₩1,503,000.00
- Day range
- ₩1,490,000.00 to ₩1,556,000.00
- 52-week range
- ₩1,228,000.00 to ₩1,987,000.00
- Volume
- 5.18만
- Average volume
- 7.72만
- Market cap
- 72.03조
- P/E ratio (TTM)
- Not available
Profile
About SAMSUNG BIOLOGICS Co., Ltd.
SAMSUNG BIOLOGICS Co., Ltd. trades on KOSPI Market, Korea Exchange under 207940 and is grouped under Health Technology. Figures marked unavailable are not estimated.
Editorial profile
SAMSUNG BIOLOGICS Co., Ltd. overview
SAMSUNG BIOLOGICS Co., Ltd. provides contract development and manufacturing services for biologic medicines. Its services cover cell-line development, process and analytical development, clinical and commercial manufacturing, fill-finish, and laboratory testing. These activities place the company in Health Technology and connect 207940 to the specific products, services, customers, and operating assets described in its official materials.
SourcesSAMSUNG BIOLOGICS Co., Ltd.207940 is the ordinary share quoted on KOSPI Market, Korea Exchange. SAMSUNG BIOLOGICS Co., Ltd.'s investor materials publish quarterly results and an annual report. This profile refers to that local security and operating group, which matters when an issuer has several venues, share classes, depositary receipts, or a name that resembles another company.
SourcesSAMSUNG BIOLOGICS Co., Ltd.SAMSUNG BIOLOGICS Co., Ltd.A genuinely distinguishing feature is that Samsung Biologics combines large-scale mammalian biologics manufacturing with end-to-end development services under a single CDMO platform. It manufactures for pharmaceutical clients rather than primarily marketing its own branded medicines. This is more precise than a broad sector label: it identifies a named platform, product architecture, network, asset base, or corporate structure that separates SAMSUNG BIOLOGICS Co., Ltd. from otherwise similar issuers.
SourcesSAMSUNG BIOLOGICS Co., Ltd.- Security type
- Ordinary Share
- Primary listing
- KOSPI Market, Korea Exchange · 207940 SourcesSAMSUNG BIOLOGICS Co., Ltd.SAMSUNG BIOLOGICS Co., Ltd.
Primary sources
- SAMSUNG BIOLOGICS Co., Ltd. official company profileSAMSUNG BIOLOGICS Co., Ltd. · Retrieved 2026-08-10
- SAMSUNG BIOLOGICS Co., Ltd. investor relationsSAMSUNG BIOLOGICS Co., Ltd. · Retrieved 2026-08-10
- 207940 listing informationSAMSUNG BIOLOGICS Co., Ltd. · Retrieved 2026-08-10
Contextual peers
Related assets
Same sector: Health Technology
Same market: South Korea
207940 questions
SAMSUNG BIOLOGICS Co., Ltd. questions
What business does 207940 represent?
207940 represents SAMSUNG BIOLOGICS Co., Ltd., which provides contract development and manufacturing services for biologic medicines. Its services cover cell-line development, process and analytical development, clinical and commercial manufacturing, fill-finish, and laboratory testing.
Which products, services, or operating markets are specifically associated with 207940?
Its services cover cell-line development, process and analytical development, clinical and commercial manufacturing, fill-finish, and laboratory testing.
What specifically distinguishes the business behind 207940?
For SAMSUNG BIOLOGICS Co., Ltd., the asset-specific distinction is that Samsung Biologics combines large-scale mammalian biologics manufacturing with end-to-end development services under a single CDMO platform. It manufactures for pharmaceutical clients rather than primarily marketing its own branded medicines.
Risk and data disclosure
Read before using this data
Glide provides this market data for informational purposes only. It is not investment advice, a recommendation, or an offer to buy or sell any asset. Prices may be delayed or incomplete. Verify market data and consider your objectives, financial situation, and professional advice before acting.